Table 1 Clinical characteristics and laboratory findings.
Malignant | Benign | Validation | p-value | |
|---|---|---|---|---|
Number of patients | 78 | 21 | 40 | … |
Age, years | 59.0 [53.2–64.8] | 53.0 [43.0–64.0] | 55.6 [47.3–62.7] | 0.040 |
Sex | … | … | … | 0.524 |
Male | 45 (57.7) | 12 (57.1) | 27 (67.5) | … |
Female | 33 (42.3) | 9 (42.9) | 13 (32.5) | … |
Clinical stages | … | … | … | 0.419 |
I | 52 (66.7) | … | 23 (57.5) | … |
II | 10 (12.8) | … | 4 (10.0) | … |
III | 13 (16.7) | … | 3 (7.5) | … |
IV | 3 (3.8) | … | 0 (0.0) | … |
T stage | … | … | … | 0.325 |
1 | 36 (46.2) | … | 14 (35.0) | … |
2 | 33 (42.3) | … | 13 (32.5) | … |
3 | 5 (6.4) | … | 2 (5.0) | … |
4 | 4 (5.1) | … | 1 (2.5) | … |
N stage | … | … | … | 0.076 |
0 | 62 (79.5) | … | 25 (52.5) | … |
1 | 3 (3.8) | … | 2 (5.0) | … |
2 | 12 (15.4) | … | 2 (5.0) | … |
3 | 1 (1.3) | … | 1 (2.5) | … |
M stage | … | … | … | < .001 |
0 | 75 (96.2) | … | 28 (70.0) | … |
1 | 3 (3.8) | … | 2 (5.0) | … |
Pathological type | … | … | … | 0.110 |
Adenocarcinoma | 52 (66.7) | … | 20 (50.0) | … |
Squamous carcinoma | 19 (24.4) | … | 7 (17.5) | … |
Other carcinoma | 7 (9.0) | … | 3 (7.5) | … |
Invasive depth | … | … | … | 0.003 |
0 | 1 (1.3) | … | 2 (5.0) | … |
1 | 8 (10.3) | … | 2 (5.0) | … |
2 | 69 (88.5) | … | 26 (65.0) | … |
Differentiation grade | … | … | … | 0.020 |
1 | 6/63 (9.5) | … | 4 (10.0) | … |
2 | 52/63 (82.5) | … | 24 (60.0) | … |
3 | 5/63 (7.9) | … | 2 (5.0) | … |
No. of pulmonary nodules | … | … | … | 0.699 |
1 | 63 (80.8) | 19 (90.5) | 35 (62.5) | … |
2 | 13 (16.7) | 2 (9.5) | 4 (10.0) | … |
3 | 2 (2.6) | 0 | 1 (2.5) | … |
TIL grade | … | … | … | 0.288 |
0 | 52/72 (72.2) | 0 | 22 (55.0) | … |
1 | 19/72 (26.4) | 1/1 (100) | 7 (17.5) | … |
2 | 1/72 (1.4) | 0 | 1 (2.5) | … |
TII | 10.0 [6.0–15.0] | 10.0 [10.0–10.0] | 10.0 [6.0–15.0] | 0.849 |
CD8 | 1.0 [1.0–1.5] | 1.0 [1.0–1.0] | 1.0 [1.0–1.0] | 0.571 |
PD-L1 | 3.0 [3.0–8.0] | 1.0 [1.0–1.0] | 3.0 [2.5–4.25] | < .001 |
CPS | 4.0 [3.0–11.0] | 1.0 [1.0–1.0] | 4.0 [1.75–11.0] | < .001 |
TIMIT | … | … | … | 1.000 |
I | 27 (37.5) | 1 (4.7) | 11 (27.5) | … |
II | 21 (29.2) | 0 | 8 (20.0) | … |
III | 7 (9.7) | 0 | 3 (7.5) | … |
IV | 17 (23.6) | 0 | 8 (20.0) | … |
Smoking | 33 (42.3) | 7 (33.3) | 17 (42.5) | 0.615 |
Macrophage | … | … | … | 0.877 |
< 5 | 57 (79.2) | 1(4.7) | 24 (60.0) | … |
5–10 | 13 (18.1) | 0 | 4 (10.0) | … |
> 10 | 2 (2.8) | 0 | 2 ( 5.0) | … |
Ki67 | 0.3 [0.1–0.6] | … | 0.3 [0.1–0.6] | … |
Tumor diameter, cm | … | … | … | … |
Imaging | 2.4 [1.6–3.6] | 2.0 [1.6–3.8] | 2.5 [1.2–3.2] | 0.562 |
Surgical | 3.0 [1.9–4.0] | 2.0 [1.5–3.5] | 2.5 [1.5–3.8] | 0.160 |
Pathological | 2.5 [1.5–4.0] | 2.0 [1.0–3.0] | 2.2 [1.5–3.8] | 0.138 |
CEA, ng/mL | 41.0 [18.3–63.8] | 21.0 [10.0–53.0] | 34.0 [10.8–55.3] | 0.092 |
NSE, ug/L | 44.5 [17.3–66.8] | 37.0 [23.0–52.0] | 42.0 [15.3–70.3] | 0.604 |
CYFRA19, ug/L | 39.0 [15.3–59.8] | 21.0 [12.0–45.0] | 32.0 [11.8–53.0] | 0.137 |
SCC , ng/mL | 10.0 [7.0–14.8] | 8.0 [5.0–12.0] | 8.0 [6.0–10.3] | 0.044 |
ProGRP, pg/mL | 34.5 [11.5–54.0] | 33.0 [18.0–56.0] | 32.5 [10.3–58.5] | 0.775 |
WBC count, × 109/L | 5.6 [4.6–7.4] | 5.7 [4.5–6.5] | 5.9 [4.6–7.6] | 0.745 |
Neutrophil count, × 109/L | 3.4 [2.5–4.7] | 3.2 [2.8–4.0] | 3.9 [2.7–5.1] | 0.619 |
Lymphocyte count, × 109/L | 1.6 [1.3–1.9] | 1.6 [1.4–1.9] | 1.5 [1.3–1.8] | 0.451 |
Hemoglobin, g/L | 133.0 [124.0–141.0] | 140.0 [119.0–152.0] | 138.0 [124.0–151.0] | 0.220 |
PLT count, × 109/L | 232.0 [181.0–260.0] | 227.0 [205.0–268.0] | 213.0 [172.0–254.5] | 0.863 |
